ArticleKidney & blood pressure research2026
Hyperuricaemia-Induced Hypertension in Rats by Regulating the RhoA/ROCK Pathway.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperuricaemia (HUA) is associated with hypertension, but the mechanisms remain unclear. This study investigated whether the RhoA/ROCK pathway mediates HUA-induced vascular remodelling and hypertension.
methodsThirty male Sprague-Dawley rats were divided into control, HUA, and fasudil (ROCK inhibitor) groups. Serum uric acid, creatinine, and blood pressure were measured biweekly. Histopathology, qPCR, and Western blotting assessed thoracic aortic changes and RhoA/ROCK pathway activation. Rat vascular smooth muscle cells (VSMCs) were treated with uric acid, with or without RhoA/ROCK inhibitors, to evaluate nitric oxide (NO) levels and protein expression.
resultsHUA significantly increased systolic blood pressure, aortic media thickness, smooth muscle cell proliferation, and expression of RhoA, ROCK 1/2, and MLC1, with elevated phosphorylation of MLC and MYPT-1. Fasudil reduced blood pressure and ameliorated vascular remodelling but did not lower uric acid levels. In VSMCs, HUA decreased NO content, enhanced RhoA membrane translocation, and increased ROCK 2 expression, effects reversed by RhoA or ROCK inhibitors.
conclusionHUA promotes hypertension by activating the RhoA/ROCK pathway, leading to vascular remodelling and dysfunction. Inhibition of this pathway attenuates HUA-induced hypertension, highlighting the mechanistic relevance of the RhoA/ROCK pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.